A Trial of GH001 in Patients With Treatment-resistant Depression

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 24, 2023

Primary Completion Date

October 4, 2024

Study Completion Date

March 11, 2025

Conditions

Treatment-resistant Depression

Interventions

DRUG

GH001

GH001 administered via inhalation

DRUG

Placebo

Placebo administered via inhalation

Trial Locations (11)

Investigational site, Pilsen

Investigational site, Prague

Investigational Site, Dresden

Investigational Site, Frankfurt

Investigational Site, Münster

Investigational site, Dublin

Investigational Site, Galway

Investigational Site, Maastricht

Investigational Site, Gdansk

Investigational Site, Barcelona

Investigational Site, Salamanca

All Listed Sponsors

lead

GH Research Ireland Limited

INDUSTRY

NCT05800860 - A Trial of GH001 in Patients With Treatment-resistant Depression | Biotech Hunter | Biotech Hunter